DOSEGUY

CMS-121

guinea pig

Also seen as: CMS121, CMS 121

The Dose Guy’s verdict
Sep 1, 2026
3 sources

CMS-121 is early but genuinely interesting. A synthetic fisetin derivative with a clean mechanism, strong rodent results across Alzheimer’s, Huntington’s, and aging models, and a phase 1 preprint that cleared safety in healthy volunteers. That is more runway than most compounds on this shelf ever build. It is also still preclinical for any real endpoint. Nobody has tested whether it helps a person think better or age slower, and there is no approved product, no finished dosage form, and no source with a COA behind it. Worth tracking, not worth running yet.

Would I take it?Caution, watch this one.

What it is

CMS-121 is a synthetic derivative of fisetin, the flavonoid found in strawberries and marketed as a longevity supplement. The Salk Institute built it to be more potent and more drug-like than fisetin itself, and the mechanism turned out to be fatty acid synthase inhibition, redirecting lipid metabolism in a way that reduces brain inflammation and oxidative damage. In aging and neurodegeneration mouse models, it consistently protects cognition, slows motor decline, and improves metabolic markers.

Fisetin itself has a following in the anti-aging community, mostly around senolytic dosing. CMS-121 is the pharmaceutical-track version of that idea, designed for oral bioavailability and aimed at neurodegeneration rather than general senescence. On the nootropic shelf it sits among the compounds with real mechanistic depth and no human proof yet.

What the research shows

Rodent work across multiple disease models, plus a phase 1 that establishes human tolerability but nothing else:

Single oral doses up to 1800 mg and repeat doses up to 900 mg per day for seven days were generally well tolerated. Exposure increased in a dose-proportional manner, and fed-state exposure was about 50% higher than fasting.2025 · phase 1 preprint · healthy adults
CMS-121 alleviated cognitive loss in Alzheimer’s model mice and identified fatty acid synthase as its molecular target, reducing brain inflammation and lipid peroxidation.Redox Biol 2020 · transgenic AD mice
CMS-121 slowed motor dysfunction and increased median lifespan in both R6/2 and YAC128 mouse models of Huntington’s disease.Biomedicines 2023 · HD mice
Elderly healthy volunteers had higher systemic exposure and longer terminal elimination half-lives than younger adults.2025 · phase 1 preprint · PK
No randomized trial or efficacy study of CMS-121 in patients with Alzheimer’s disease, dementia, or Huntington’s disease exists in the indexed literature.as of Aug 2026

Realistic protocols

CMS-121 has no approved product or finished dosage form. A phase 1 preprint cleared it for safety, which means doses up to 900 mg daily for a week did not cause serious problems in healthy volunteers, but no efficacy dose has been established and no patient has been treated in a trial. The phase 1 tells you CMS-121 is tolerable, not that it works at any particular dose. If fisetin’s neuroprotective angle appeals to you, fisetin itself is available, cheap, has a longer safety record, and carries its own senolytic and anti-inflammatory story, though its clinical evidence for cognition is thin. CMS-121 is the one to watch for trial results, not the one to self-experiment with today.

Side effects

Phase 1 side-effect data from healthy volunteers only:

commonMost adverse events in phase 1 were mild. No specific pattern dominated.
monitorElderly volunteers showed higher drug exposure and slower elimination than younger adults. Age-related dosing differences are likely.
unknownNo patient population has been dosed. Phase 1 in healthy adults sets a floor for tolerability, not a ceiling for risk in disease.

Where to buy

No live listings from tracked vendors right now.